<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04686929</url>
  </required_header>
  <id_info>
    <org_study_id>SZ9102</org_study_id>
    <nct_id>NCT04686929</nct_id>
  </id_info>
  <brief_title>Abatacept s.c. for aGVHD Prevention in Haplo-HCT</brief_title>
  <official_title>The Efficacy and Safety of Subcutaneous Abatacept in the Prevention of Acute Graft-versus-host Disease After Haplo-identical Donor Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute graft-versus-host disease (aGVHD) is a potentially fatal complication after allogeneic&#xD;
      hematopoietic cell transplantation (HCT), particularly for that with a HLA-mismatched donor.&#xD;
      Abatacept has been demonstrated as a potent drug to reduce the risk of aGVHD, but the&#xD;
      efficacy of subcutaneous form has yet been investigated. This trial is designed to&#xD;
      preliminarily determin the efficacy and saftey of subcutaneous abatacept in the prevention of&#xD;
      aGVHD after haplo-identical HCT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of overt aGVHD</measure>
    <time_frame>100 days post-HCT</time_frame>
    <description>The incidence of grade II-IV aGVHD post-transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of aGVHD</measure>
    <time_frame>100 days post-HCT</time_frame>
    <description>The incidence of grade I-IV aGVHD post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe aGVHD</measure>
    <time_frame>100 days post-HCT</time_frame>
    <description>The incidence of grade III-IV aGVHD post-transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early transplant-related mortality</measure>
    <time_frame>100 days post-HCT</time_frame>
    <description>The incidence of early transplant-related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>100 days post-HCT</time_frame>
    <description>The incidence of relapse/progression of underlying disease</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Engraft failure</measure>
    <time_frame>100 days post-HCT</time_frame>
    <description>Failed to engraft with donor cells</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood cell recovery</measure>
    <time_frame>100 days post-HCT</time_frame>
    <description>Neutrophil count recover to 1000/ul and platelet count recover to 20000/ul</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Abatacept</condition>
  <condition>Acute-graft-versus-host Disease</condition>
  <condition>Haplo-identical HCT</condition>
  <condition>Prevention</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants in Cohort 1 will receive a lower dose of abatacept s.c as maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants in Cohort 2 will receive a higher dose of abatacept s.c as maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lower dose of abatacept</intervention_name>
    <description>subcutaneous abatacept: 250mg (d-1) , 125mg (d+5, +14, +21, +28, +35, +42, +49, +56) combined with CsA, MTX, MMF.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Higher dose of abatacept</intervention_name>
    <description>subcutaneous abatacept: 250mg (d-1, +5, +14, +21, +28, +35, +42, +49, +56) combined with CsA, MTX, MMF.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age≧18 years&#xD;
&#xD;
          2. ECOG score 0-2 / Karnofsky score≧80&#xD;
&#xD;
          3. haplo-HCT is proposed&#xD;
&#xD;
          4. Conditioning with motified Bu/Cy+ATG regimen&#xD;
&#xD;
          5. Having the following hematologic malignancies with transplant indications:&#xD;
&#xD;
               1. Acute leukemia&#xD;
&#xD;
               2. Myelodysplastic syndrome&#xD;
&#xD;
               3. Aggressive lymphoma&#xD;
&#xD;
          6. Expected survival ≥ 3 months&#xD;
&#xD;
          7. Written informed Consent can be acquired&#xD;
&#xD;
          8. Agree to use effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With a history of allo-HCT previously&#xD;
&#xD;
          2. Allergic/intolerant to Abatacept&#xD;
&#xD;
          3. Contraindications to the use of Abatacept&#xD;
&#xD;
          4. HIV infection, or active HBV infection or HCV infection&#xD;
&#xD;
          5. Uncontrolled active infection&#xD;
&#xD;
          6. Vital organ function intolerated to transplantation&#xD;
&#xD;
          7. Other malignancies except for the following diseases: malignant tumors that have been&#xD;
             cured for at least 3 years without active lesions; adequete treated non-melanoma skin&#xD;
             cancer, malignant amygdala, and carcinoma in situ without active lesions&#xD;
&#xD;
          8. Evidence of complications or medical conditions that may interfere with research or&#xD;
             put the subjects at serious risk, including but not limited to severe cardiovascular&#xD;
             disease (e.g. New York Heart Association grade III or IV heart disease, myocardial&#xD;
             infarction in the past 6 months, unstable arrhythmia or unstable angina) and/or severe&#xD;
             lung disease (e.g. history of severe obstructive lung disease and symptomatic&#xD;
             bronchospasm)&#xD;
&#xD;
          9. Pregnant and lactational women&#xD;
&#xD;
         10. Any life-threatening disease, medical condition, or organ dysfunction unfit for&#xD;
             participants, or may interfere with the absorption or metabolism of Abatacept&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia Chen, M.D.</last_name>
    <phone>+86 512 6778 1856</phone>
    <email>drchenjia@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiang Zhang</last_name>
    <phone>+86 512 6778 1850</phone>
    <email>lcsy2013@sina.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Chen, M.D.</last_name>
      <phone>+86 512 67781856</phone>
      <email>chenjiasuzhou@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Soochow University</investigator_affiliation>
    <investigator_full_name>CHEN Jia</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

